Young Kwok, MD
Education and Training
Undergraduate: Johns Hopkins University, 1995
Medical School: Albert Einstein College of Medicine, 1999
Internship: Beth Israel Medical Center, 2000
Residency: University of Maryland Medical Center, 2004
Flannery TW,Suntharalingam M, Regine WF, Chin LS, Krasna MJ, Shehata MK, Edelman MJ, Kremer M, Patchell RA, and Kwok Y. Long-term survival in patients with synchronous, solitary brain metastasis from non-small cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys 2008 Sept 1;72(1):19-23. Epub 2008 Feb 13.
DiBiase SJ, Hussain A, Kataria R, Amin P, Bassi S, Dawson N, and Kwok Y. Long-term results of a prospective, phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost and adjuvant docetaxel in patients with high-risk prostate cancer. International Journal of Radiation Oncology Biology Physics 2011;81(3):732-6. Epub 2010 Oct30.
Koshy M, Rich SE, Mahmood U, Feigenberg S, and Kwok Y. The Declining Utilization of Radiation Therapy in Stage I and II Hodgkin’s Disease and its Impact on Survival and Secondary Malignancies. International Journal of Radiation Oncology Biology Physics 2011; 105(3): 583-90.
Koshy M, Rich S, Merchant E, Mahmood U, Regine W, and Kwok Y. Post-operative Radiation Improves Survival in Children Younger Than 3 Years with Intracranial Ependymoma. Journal of Neuro-oncology. 2011;105(3):583-90. Epub 2011 June 3.
Hussain A, Wu Y, Mirmiran A, DiBiase S, Goloubeva O, Bridges, Mannuel H, Engstrom C, Dawson N, Amin P and Kwok Y. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation and androgen deprivation in high risk prostate cancer with or without prior prostatectomy. International Journal of Radiation Oncology Biology Physics 2012;82(1):167-74. Epub 2010 Oct 30.
Rogers CL, Perry A, Pugh S, Vogelbaum MA, Brachman D, McMillan W, Jenrette J, Barani I, Shrieve D, Sloan A, Bovi J, Kwok Y, Burri SH, Chao ST, Spalding AC, Anscher MS, Bloom B, Mehta M. Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol 2015;Oct 22 [Epub ahead of print].
Gilbert M, Pugh S, Aldape K, Sorensen G, Walker E, Penas-Prado M, Corn B, Kwok Y, Choucair A, Mehta M. RTOG 0625: A Randomized Phase II Trial of Bevacizumab with either Irinotecan or Dose-Dense Temozolomide in Recurrent Glioblastoma. Journal of Neuro-Oncology 2016.
Central Nervous System Malignancies
Phase II Trial of Low-Dose Whole Brain Radiotherapy with Concurrent Temozolomide and Adjuvant Temozolomide in Patients with Newly-Diagnosed Glioblastoma Multiforme
Role: Principal Investigator
Pilot Trial of Combined novoTTF-100A, Bevacizumab and Hypofractionated Stereotactic Irradiation for Bevacizumab-naive, Recurrent Glioblastoma